Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A landmark phase 3 trial showed that adding a personalized mRNA cancer vaccine to standard immunotherapy dramatically cuts the risk of melanoma coming back after surgery. The INTerpath-001 trial found that intismeran autogene plus pembrolizumab reduced the risk of recurrence or death by 42% and distant metastasis or death by 38% compared to pembrolizumab alone. Researchers are calling it a defining moment for personalized cancer medicine.
A personalized mRNA cancer vaccine is making waves in melanoma treatment. Results from the phase 3 INTerpath-001 trial, presented at the 2026 ESMO Congress, showed that adding intismeran autogene (mRNA-4157) to the immunotherapy pembrolizumab significantly reduced the risk of cancer returning after surgery in patients with high-risk, resected stage IIB–IV melanoma. The vaccine is individually tailored to each patient's tumor, encoding up to 34 neoantigens unique to their cancer.
At a median follow-up of nearly 25 months, the combination outperformed pembrolizumab alone on every key measure. Lead investigator Dr. Georgina Long called it "a new benchmark for adjuvant treatment in melanoma" and a landmark advance in personalized cancer medicine. OS data are still maturing, and full results are set for publication in the New England Journal of Medicine in November 2026.
By the Numbers:
Why it matters: This is the first phase 3 trial to validate a personalized mRNA cancer vaccine, marking a potential paradigm shift in how oncologists treat resected melanoma — and possibly other cancers like lung, bladder, and renal cell carcinoma down the line.
